Ashland Inc. (NYSE: ASH) is a Basic Materials company in the Chemicals - Specialty industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 61.12 | EPS (ttm) | 1.13 | Insider Own | 1.55% | Shs Outstand | 45.79M | Perf Week | -2.61% |
| Market Cap | 3.16B | Forward P/E | 16.04 | EPS next Y | 4.31 | Insider Trans | 0.00% | Shs Float | 41.05M | Perf Month | -4.71% |
| Enterprise Value | 4.18B | PEG | 3.36 | EPS next Q | 1.32 | Inst Own | - | Short Float | 11.74% | Perf Quarter | 1.68% |
| Income | 52.00M | P/S | 1.72 | EPS this Y | 212.27% | Inst Trans | - | Short Ratio | 5.49 | Perf Half Y | 37.60% |
| Sales | 1.84B | P/B | 1.69 | EPS next Y | 22.02% | ROA | 1.14% | Short Interest | 4.82M | Perf YTD | 17.71% |
| Book/sh | 40.84 | P/C | 7.19 | EPS next 5Y | 18.17% | ROE | 2.77% | 52W High | 78.25 -11.74% | Perf Year | 35.15% |
| Cash/sh | 9.61 | P/FCF | 10.05 | EPS past 3/5Y | - | ROIC | 1.94% | 52W Low | 46.30 49.16% | Perf 3Y | -15.00% |
| Dividend Est. | 1.68 (2.43%) | EV/EBITDA | 10.72 | Sales past 3/5Y | -8.63% -1.98% | Gross Margin | 29.35% | Volatility | 2.49% 2.58% | Perf 5Y | -25.37% |
| Dividend TTM | 1.67 (2.42%) | EV/Sales | 2.27 | EPS Y/Y TTM | -66.57% | Oper. Margin | 7.33% | ATR (14) | 2.01 | Perf 10Y | 19.07% |
| Dividend Ex-Date | Sep 01, 2026 | Quick Ratio | 1.89 | Sales Y/Y TTM | -12.78% | Profit Margin | 2.82% | RSI (14) | 37.36 | Recom | 2.36 |
| Dividend Gr. 3/5Y | 8.13% 8.45% | Current Ratio | 3.05 | EPS Q/Q | -8.08% | SMA20 | -4.57% | Beta | 0.40 | Target Price | 78.71 |
| Payout | 146.15% | Debt/Eq | 0.83 | Sales Q/Q | 7.34% | SMA50 | -3.34% | Rel Volume | 1.39 | Prev Close | 69.77 |
| Employees | 2,900 | LT Debt/Eq | 0.82 | Earnings | Nov 03 | SMA200 | 11.24% | Avg Volume | 791.09K | Price | 69.06 |
| IPO Date | Mar 17, 1980 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -4.99% -0.74% | Net Debt/EBITDA | 2.66 | Volume | 1,097,141 | Change | -1.02% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-06-26 | Reiterated | Morgan Stanley | Equal Weight | $58 → $78 |
| Jul-31-26 | Reiterated | Deutsche Bank | Buy | $74 → $85 |
| Jul-30-26 | Reiterated | UBS | Buy | $72 → $83 |
| Jul-29-26 | Reiterated | BMO Capital | Outperform | $71 → $75 |
| Jul-29-26 | Reiterated | Mizuho | Outperform | $70 → $77 |
| Jul-27-26 | Reiterated | Wolfe Research | $110 → $78 | |
| Jun-10-26 | Reiterated | UBS | Buy | $73 → $72 |
| May-06-26 | Upgrade | Seaport Global | Neutral → Buy | $75 |
| May-04-26 | Reiterated | Morgan Stanley | $63 → $58 | |
| May-01-26 | Reiterated | Deutsche Bank | Buy | $70 → $60 |
Ashland Inc. operates as a global supplier of specialized chemicals and additives. Its business activities are structured into four main divisions: Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents. The Life Sciences segment delivers pharmaceutical formulations, encompassing controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and binding agents for tablets. It also offers nutritional compounds like thickeners, stabilizers, emulsifiers, and various additives, alongside nutraceutical items designed for weight management, joint comfort, gastrointestinal health, sports nutrition, and general well-being. Additionally, this division provides custom formulation services, toll processing, and particle engineering expertise. The Personal Care & Household division manufactures a diverse array of naturally derived, biodegradable, and high-performance ingredients for personal care products. Its offerings extend to solutions for oral hygiene, such as toothpastes, mouthwashes, denture cleansers, and general dental care. For household applications, it supplies nature-sourced rheology modifiers, biodegradable wetting agents for surfaces, advanced encapsulants, and specialized polymers. The Specialty Additives segment's portfolio includes rheology modifiers, agents for foam control, surfactants, wetting agents, pH neutralizers, and advanced ceramic materials, which find application in catalytic converters, environmental filters, components for ceramic capacitors, plasma display panels, and solar cells. Furthermore, it supplies ingredients for textile printing, thermoplastic metals, and alloys utilized in welding processes. The Intermediates and Solvents division is responsible for producing 1,4 butanediol and its associated derivatives, notably n-methylpyrrolidone. Ashland's diverse product portfolio serves clientele across numerous consumer and industrial sectors, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceuticals. The company, previously known as Ashland Global Holdings Inc., was established in Wilmington, Delaware, in 1924.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 9/30/2025 | FY 2024 9/30/2024 | FY 2023 9/30/2023 | FY 2022 9/30/2022 | FY 2021 9/30/2021 | FY 2020 9/30/2020 | FY 2019 9/30/2019 | FY 2018 9/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,843 | 1,824 | 2,113 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,302 | 1,275 | 1,495 | — | — | — | — | — | — | |
| Gross Profit | 541 | 549 | 618 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 324 | 345 | 404 | — | — | — | — | — | — | |
| Research and Development | 55 | 54 | 55 | — | — | — | — | — | — | |
| Other Operating Expense | 27 | 925 | 185 | — | — | — | — | — | — | |
| Operating Income | 135 | -775 | -26 | — | — | — | — | — | — | |
| Interest Expense | 61 | 63 | 53 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 51 | 29 | 55 | — | — | — | — | — | — | |
| Net Income Before Taxes | 125 | -809 | -24 | — | — | — | — | — | — | |
| Income Taxes | 50 | 13 | -223 | — | — | — | — | — | — | |
| Consolidated Net Income | 52 | -845 | 169 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 75 | -822 | 199 | — | — | — | — | — | — | |
| Net Income | 52 | -845 | 169 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.14 | -18.37 | 3.45 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.14 | -18.37 | 3.45 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.13 | -18.37 | 3.38 | — | — | — | — | — | — | |
| EBITDA | 390 | -509 | 303 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 61.12 | — | 25.73 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.72 | 1.21 | 2.02 | — | — | — | — | — | — | |
| Gross Margin | 29.35 | 30.10 | 29.25 | — | — | — | — | — | — | |
| Operating Margin | 7.33 | -42.49 | -1.23 | — | — | — | — | — | — | |
| Net Margin | 2.82 | -46.33 | 8.00 | — | — | — | — | — | — | |
| Shares Outstanding | 46 | 46 | 49 | — | — | — | — | — | — | |
| Market Capitalization | 3,177 | 2,204 | 4,262 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| LAMPKIN ROBIN E. | SVP, GC & Secretary | Aug 11 '26 | Option Exercise | 37.29 | 3,612 | 134,691 | 6,825 | Aug 12 |
| MUSA OSAMA M | SVP and CTO | Jul 29 '26 | Option Exercise | 57.96 | 11,060 | 641,037 | 30,806 | Jul 30 |
| Assis Alessandra Faccin | SVP and GM, Life Sciences | Jul 27 '26 | Option Exercise | 66.38 | 3,215 | 213,412 | 9,099 | Jul 29 |
| MINICUCCI JAMES P. | SVP and GM, Personal Care | May 08 '26 | Option Exercise | 55.01 | 4,310 | 237,093 | 8,567 | May 11 |
| Kulkarni Ashish K | Director | Jan 21 '26 | Option Exercise | 0.00 | 4,226 | 0 | 2,113 | Jan 22 |
| LAMPKIN ROBIN E. | SVP, Gen Counsel and Secrty. | Nov 17 '25 | Option Exercise | 49.60 | 239 | 11,854 | 5,095 | Nov 19 |
| NOVO GUILLERMO | Chair of the Board and CEO | Nov 17 '25 | Option Exercise | 49.60 | 6,122 | 303,651 | 143,412 | Nov 19 |
| Drury Eileen | SVP and Chief HRO | Nov 17 '25 | Option Exercise | 49.60 | 567 | 28,123 | 7,881 | Nov 19 |
| MUSA OSAMA M | SVP and CTO | Nov 17 '25 | Option Exercise | 49.60 | 976 | 48,410 | 29,875 | Nov 19 |
| RICHARDSON SAMUEL | VP, Controller and PAO | Nov 17 '25 | Option Exercise | 49.60 | 107 | 5,307 | 1,104 | Nov 19 |
| WHITAKER WILLIAM | SVP, CFO & PFO | Nov 17 '25 | Option Exercise | 49.60 | 107 | 5,307 | 2,082 | Nov 19 |
| MUSA OSAMA M | SVP and CTO | Nov 14 '25 | Option Exercise | 51.51 | 2,091 | 107,707 | 29,616 | Nov 19 |
| MUSA OSAMA M | SVP and CTO | Nov 13 '25 | Option Exercise | 53.10 | 1,393 | 73,968 | 28,002 | Nov 19 |
| LAMPKIN ROBIN E. | SVP, Gen Counsel and Secrty. | Nov 14 '25 | Option Exercise | 51.51 | 1,276 | 65,727 | 5,237 | Nov 17 |
| NOVO GUILLERMO | Chair of the Board and CEO | Nov 14 '25 | Option Exercise | 51.51 | 9,119 | 469,720 | 141,107 | Nov 17 |